Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01412190
Other study ID # 31GR0803
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2009
Est. completion date July 2010

Study information

Verified date November 2012
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and efficacy of Restylane Vital White administered with an injector device on aged skin in the face, hands and décolletage.


Description:

The objectives are to explore the safety and efficacy profile of Restylane Vital White administered with an injector device when one side of the face, one of the hands and one side of the décolletage is treated and the other side of the face, the other hand and the other side of the décolletage is left untreated. The face, the hands and the décolletage will be evaluated separately for both the efficacy and the safety parameters.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2010
Est. primary completion date July 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: - Signed informed consent obtained - Female subjects 40-65 years of age, inclusive. - Visible signs of skin aging in the face, hands and décolletage (e.g. reduced skin elasticity, reduced turgor, actinic elastosis, smaller and larger wrinkles) according to the Investigators opinion. - Subjects must be cooperative and willing to comply with the instructions and procedures. Exclusion Criteria: - Extensively photo damaged and aged skin according to the Investigators opinion. - Active skin disease, inflammation or related conditions, such as infection, perioral dermatitis, seborrheic eczema and rosacea in the face, hands or décolletage. - History of or active collagenosis (e.g. systemic lupus, erythematosis, Rheumatic arthritis, skin or systemic sclerosis) - Previous hypersensitivity to hyaluronic acid. - Concomitant therapy with thrombolytics or anticoagulants, or have taken inhibitors of platelet aggregation, within 2 weeks before the baseline visit. - History of cancerous or pre-cancerous lesions in the face, hands and décolletage. - Previous tissue augmenting therapy with non-permanent filler or treatment with botulinum toxin, aesthetic surgical therapy, laser treatment, mesotherapy, or any form of peeling in the face, hands or décolletage within 12 months prior to the baseline visit. - Use of injectable revitalization preparations (e.g. Hyal System®, Restylane Vital) within 12 months prior to the baseline visit. - Use of retinoic acid within 6 months prior to the baseline visit. - Previous or concomitant treatment with chemotherapy, immunosuppressive agents or corticoids. - History of treatment with permanent filling materials. - Pregnancy or breast feeding woman or woman of childbearing potential not practicing adequate contraception. - Participation in any other clinical study within 30 days prior to the baseline visit or plan to participate in another clinical study during this study period. - Unrealistic expectation with regard to the esthetic results of the treatment. - Planned or ongoing weight reduction program during the study. - Known history of drug or alcohol abuse within 6 months prior to the baseline visit. - Known hypersensitivity to one or more components of EMLA cream®. - Any medical condition that in the opinion of the Investigator makes the subject unsuitable for inclusion (e.g. severe chronic disease, malignancy, bleeding disorder, skin diseases etc). - Other condition preventing the subject to entering the study in the Investigator's opinion e.g. subjects anticipated to be unreliable, unable to return for the follow-up visits, not likely to avoid other prohibited treatments or procedures or incapable of understanding the information or instructions. - Nicotine use during the study or stopped within 12 months before the baseline visit. - Study staff or close relative of study staff (e.g. parents, children, siblings and spouse).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Restylane Vital Light
Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
Other:
No treatment
One side of face, one hand and one side of the décolletage is left untreated as a control.

Locations

Country Name City State
Germany University of Hamburg Hamburg

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Elasticity To evaluate the change in elasticity from baseline for the treated and untreated side respectively. 0,4,8,12,20,28,36 weeks
Primary GEIS subject To evaluate esthetic change from baseline as judged by the subjects using GEIS for the treated and untreated side respectively 4,8,12,20,28,36 weeks
Primary GEIS blinded evaluator To evaluate esthetic change from baseline as judged by the blinded evaluator using GEIS for the treated and untreated side respectively, 12,20,28,36 weeks
Primary Skin structure To evaluate the change in skin structure from baseline for the treated and untreated side respectively. 0,4,8,12,20,28,36 weeks
Primary Subject satisfaction To evaluate subject satisfaction 0,12,20,28,36 weeks
Primary Best skin quality by blinded live evaluation To evaluate best skin quality of treated and untreated side judged by a blinded live evaluation 12,20,28,36 weeks
Secondary Adverse Events To evaluate the safety of Restylane Vital White during the whole study by collecting Adverse Events 0-36 weeks
Secondary Subject diary To evaluate the acute safety profile, i.e. treatment procedure reactions by direct questioning to subjects in a diary used daily for 2 weeks after each injection. 2 weeks after each treatment
See also
  Status Clinical Trial Phase
Completed NCT04505319 - Clinical Evaluation of the Safety and Performance of a Filler in Correction of Mid-face Age-related Volume Deficit N/A
Completed NCT02297516 - Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment Phase 4
Active, not recruiting NCT05355454 - Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face N/A
Completed NCT02703740 - Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds N/A
Recruiting NCT05747456 - Study of a Novel Hyaluronic Acid Based Gel for Volume Deficiency in the Mid-face (FaceHyal) N/A
Withdrawn NCT00845078 - Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer N/A